<DOC>
	<DOCNO>NCT01479504</DOCNO>
	<brief_summary>This study multicenter trial.The primary objective estimate short-term efficacy acute toxicity nedaplatin combination docetaxel neoadjuvant chemotherapy follow nedaplatin concurrent chemoradiotherapy , compare cisplatin combination docetaxel neoadjuvant chemotherapy follow cisplatin concurrent chemoradiotherapy patient locoregionally advanced nasopharyngeal carcinoma . Secondary objective evaluate overall survival , distant metastasis free survival , disease free survival patient locoregionally advanced nasopharyngeal carcinoma treat regimens.Furthermore , analyze cost-effectiveness regimen .</brief_summary>
	<brief_title>A Multicenter Trial Evaluating Efficacy Nedaplatin Patients With Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>Patients clinical stage T3-4N1/N2-3 ( UICC 7th edition ) divide two group accord informed consent : intensity-modulated radiation therapy（IMRT）group conventional fractionation radiotherapy ( CRT ) group . Then patient IMRT group/CRT group randomly assign receive nedaplatin+docetaxel neoadjuvant chemotherapy plus nedaplatin alone concurrent chemoradiotherapy cisplatin+docetaxel neoadjuvant chemotherapy plus cisplatin alone concurrent chemoradiotherapy.Evaluate overall survival , distant metastasis free survival , disease free survival patient treat regimens.Furthermore , analyze cost-effectiveness regimen .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>histologically proven nasopharyngeal carcinoma primary treatment radical intent nonkeratinizing undifferentiated type clinical stage IIIIVb ( UICC 7th edition ) age 1870 satisfactory performance status : Karnofsky scale ( KPS ) &gt; 70. hemoglobin &gt; 100g/L , WBC &gt; 4.0x10*9/L , Plt &gt; 100x10*9/L serum creatinine level &lt; 1.6 mg/dL creatinine clearance ≥ 60 mL/min . normal liver function test : Alanine Aminotransferase ( ALT ) 、Aspartate Aminotransferase ( AST ) &lt; 1.5×upper limit normal ( ULN ) concomitant alkaline phosphatase ( ALP ) ≤2.5×ULN , bilirubin ≤1.5ULN patient must inform investigational nature study give write informed consent . anticipated life span 6 month primary treatment palliative intent WHO Type keratinize squamous cell carcinoma basaloid squamous cell carcinoma Evidence distant metastasis pregnancy lactation history previous radiotherapy ( except nonmelanomatous skin cancer outside intend RT treatment volume ) . prior chemotherapy surgery ( except diagnostic ) primary tumor node prior malignancy except adequately treat basal cell squamous cell skin cancer , insitu cervical cancer cancer patient diseasefree 5 year severe intercurrent disease , may bring unacceptable risk affect compliance trial , example , unstable cardiac disease require treatment , renal disease , chronic hepatitis , diabetes poor control ( fast plasma glucose &gt; 1.5×ULN ) , emotional disturbance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Nasopharyngeal Carcinoma</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>concurrent chemoradiotherapy</keyword>
	<keyword>Nedaplatin</keyword>
</DOC>